Table 1. Percent inhibition of Tat-transactivation after depleting anti-Tat antibodies and IgG fractions of the plasma.

profiles of response	No.	Tat	inhibition (%)a	inhibition (%)b	inhibition (%)c
Full potential response	1	3.216	74.01	27.59	43.85
	2	1.166	76.83	30.87	39.63
	3	0.774	80.95	13.68	20.54
Combined response(N preferred reaction)	4	1.861	70.36	38.43	47.42
	5	0.681	82.45	22.74	36.72
	6	0.476	78.60	17.25	15.37
	7	1.561	74.54	26.36	37.31
	9	1.706	72.19	19.14	38.95
N-specific response	17	0.264	70.28	11.31	17.29
	18	0.271	68.27	16.95	13.28
monoclonal Tat antibody		2.518	75.25	12.58	11.95
HIV+Tat-	1	0.065	22.55	20.12	18.70
	2	0.06	18.18	15.20	19.12
	3	0.051	9.41	8.57	7.31
	4	0.053	26.37	19.26	22.12
	5	0.058	17.66	15.33	13.15
	6	0.053	7.33	10.02	9.87
	7	0.054	15.79	11.78	9.96
	8	0.067	23.28	12.12	17.83
	9	0.063	13.75	14.00	12.26
	10	0.062	12.65	10.98	12.82
HIV-	1	0.087	11.47	12.42	13.16
	2	0.076	18.59	10.78	17.89
	3	0.058	23.43	18.72	21.10
	4	0.071	8.39	10.80	7.89
	5	0.072	19.34	16.54	13.32
	6	0.071	3.23	5.33	7.88
	7	0.083	15.55	10.40	7.97
	8	0.064	24.93	15.87	16.89
	9	0.087	16.72	17.80	14.38
	10	0.067	9.78	11.20	7.72

All sera were diluted at 1:50 for Tat-neutralization assay. The ELISA OD values and inhibition of Tat-transactivation (inhibition (%)) are shown. “No.” represents the number of each plasma sample. ^a % inhibition of Tat-transactivation after depleting non-specific Tat antibodies with coated pPEPTIDE2 by ELISA. ^b % inhibition of Tat-transactivation after depleting Tat antibodies with coated Tat by ELISA. ^c % inhibition of Tat-transactivation after depleting IgG fractions with coated protein G by ELISA.